Loading…
Purple Biotech Ltd is projected to rise to $2.02 by 2027, a +27% move from its current price of $1.60. PPBT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.52 | $1.60 | $1.67 | +0.06% |
| Jul 14 | $1.50 | $1.60 | $1.71 | +0.11% |
| Jul 15 | $1.47 | $1.60 | $1.73 | +0.17% |
| Jul 16 | $1.46 | $1.60 | $1.75 | +0.23% |
| Jul 17 | $1.44 | $1.60 | $1.77 | +0.28% |
| Jul 18 | $1.43 | $1.60 | $1.79 | +0.34% |
| Jul 19 | $1.42 | $1.60 | $1.81 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.42 | $1.60 | $1.81 | +0.40% |
| Week 2 | $1.35 | $1.61 | $1.91 | +0.80% |
| Week 3 | $1.30 | $1.61 | $2.00 | +1.20% |
| Week 4 | $1.27 | $1.62 | $2.07 | +1.60% |
| Week 5 | $1.24 | $1.63 | $2.14 | +2.01% |
| Week 6 | $1.21 | $1.63 | $2.21 | +2.41% |
| Week 7 | $1.18 | $1.64 | $2.27 | +2.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Purple Biotech Ltd is a clinical-stage healthcare company focused on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy.
The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company was incorporated in 1968 and is headquartered in Rehovot, Israel.
Purple Biotech Ltd (PPBT) is a clinical-stage healthcare company focused on oncology therapies. The stock is trading at $1.69 per share with a market capitalization of $1.58M and a rank of 5484. The company operates in a small-cap space with an oncology-focused pipeline spanning Phase 2 assets and preclinical programs, and maintains a collaboration with Bristol Myers Squibb to evaluate CM24 with nivolumab.
The multi-year forecast shows a path to higher prices, with 2026 avg $1.69, rising to 2050 avg $5.37, and ROIs up to 217.8%. Forecast sentiment shifts from neutral in 2026 to bullish in several later years.
A major floor 67.9% below — a decisive break under it would weaken the trend.
The nearest floor, 3.4% below — buyers have tended to step in here.
The nearest ceiling, 93.7% above — a clean break opens room to run.
A major ceiling 214.7% above — clearing it would confirm fresh momentum.
Key PPBT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PPBT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.62 | Sell | $1.61 | Sell |
| MA 10 | $1.66 | Sell | $1.67 | Sell |
| MA 20 | $1.68 | Sell | $1.87 | Sell |
| MA 50 | $2.75 | Sell | $2.60 | Sell |
| MA 100 | $3.59 | Sell | $3.77 | Sell |
| MA 200 | $5.25 | Sell | $8.06 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 30.72 | Neutral |
| Stoch RSI (14) | 60.58 | Neutral |
| CCI (20) | -132.79 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.05 | Buy |
| ROC (12) | -12.15 | Sell |
| Bollinger %B (20,2) | 0.08 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -2.24 | Sell |
| Awesome (5,34) | -0.58 | Sell |
| Ultimate (7,14,28) | 35.72 | Neutral |
| Momentum (10) | -0.20 | Sell |
| Aroon Osc (25) | -20.00 | Sell |
| Hull MA (9) | 1.56 | Buy |
| ADX (14) | 36.89 | Sell |
| ATR (14) | 0.10 | Info |
The 14-day RSI is 20, indicating the stock is in oversold territory. The stock trades below key moving averages, with SMA50 listed at $3.67 and SMA200 at $5.85. Near-term support is at $1.54 and resistance at $4.22. Over the last 30 days, the price traded in a range from $1.11 to $2.58.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.54 | $1.60 | $2.24 | 0% | Neutral | |
| $1.50 | $2.02 | $2.92 | +27% | Bullish | |
| $1.53 | $2.16 | $3.31 | +35% | Bullish | |
| $1.35 | $1.99 | $3.18 | +25% | Bullish | |
| $1.15 | $1.77 | $2.94 | +11% | Neutral | |
| $1.12 | $1.79 | $3.07 | +12% | Neutral | |
| $1.09 | $1.81 | $3.18 | +13% | Neutral | |
| $1.36 | $2.32 | $4.20 | +46% | Bullish | |
| $1.49 | $2.62 | $4.84 | +64% | Bullish | |
| $1.35 | $2.46 | $4.64 | +54% | Bullish | |
| $1.58 | $3.31 | $6.82 | +108% | Bullish | |
| $2.14 | $4.76 | $10.94 | +198% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.54 | $1.60 | $1.93 | +0.00% |
| August 2026 | $1.31 | $1.57 | $1.97 | -1.36% |
| September 2026 | $1.38 | $1.68 | $2.14 | +6.77% |
| October 2026 | $1.41 | $1.74 | $2.25 | +3.60% |
| November 2026 | $1.35 | $1.67 | $2.18 | -4.00% |
| December 2026 | $1.35 | $1.69 | $2.24 | +1.25% |
Click any year to see its month-by-month PPBT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PPBT is projected to trade between $1.54 and $2.24, averaging $1.60 — a potential gain of 0% from today's $1.60. A consolidation phase looks the most probable path here.
Purple Biotech Ltd's 2027 outlook centres on $2.02, within a $1.50 to $2.92 range. That is up +27% on the projected 2026 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2028, PPBT could reach as high as $3.31, with a base case around $2.16 and support toward $1.53 — roughly +35% from $1.60. Buyers look set to stay in control over this stretch.
Expect PPBT to range from $1.35 to $3.18 through 2029. The $1.99 average target implies a +25% move from current prices. That is -8% versus the projected 2028 average. Momentum favours further upside here.
The PPBT price prediction for 2030 points to an average of $1.77 (low $1.15, high $2.94) — a potential gain of +11% on today's $1.60. A consolidation phase looks the most probable path here.
In 2031, PPBT is projected to trade between $1.12 and $3.07, averaging $1.79 — a potential gain of +12% from today's $1.60. That is up +1% on the projected 2030 average. Price action looks broadly range-bound.
Purple Biotech Ltd's 2032 outlook centres on $1.81, within a $1.09 to $3.18 range. That is up +1% on the projected 2031 average. That marks a +13% change versus current levels. A consolidation phase looks the most probable path here.
By 2033, PPBT could reach as high as $4.20, with a base case around $2.32 and support toward $1.36 — roughly +46% from $1.60. Momentum favours further upside here.
Expect PPBT to range from $1.49 to $4.84 through 2034. The $2.62 average target implies a +64% move from current prices. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The PPBT price prediction for 2035 points to an average of $2.46 (low $1.35, high $4.64) — a potential gain of +54% on today's $1.60. Momentum favours further upside here.
In 2040, PPBT is projected to trade between $1.58 and $6.82, averaging $3.31 — a potential gain of +108% from today's $1.60. That is up +35% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Purple Biotech Ltd's 2050 outlook centres on $4.76, within a $2.14 to $10.94 range. That is up +44% on the projected 2040 average. That marks a +198% change versus current levels. Momentum favours further upside here.
Investing $1,000 in PPBT today (≈ 626.959248 PPBT) could be worth
$2,981.46
+$1,981.46 (+198%) by 2050 · US Dollar
Based on the average projected PPBT price of $4.76 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PPBTwould be worth at today's price.
$1,000 invested in PPBT on Jul 10, 2025 (≈ 39.682538 PPBT) would be worth
$63.29
-$936.71 (-93.7%) today · 0.06× · US Dollar
Based on a PPBT entry price of $25.2 vs. today's $1.6.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.7 | $938.24 | -6.2% |
| 1 month ago | $2.96 | $538.85 | -46.1% |
| 3 months ago | $4.13 | $386.2 | -61.4% |
| 6 months ago | $6.8 | $234.56 | -76.5% |
| 1 year ago | $25.2 | $63.29 | -93.7% |
| All time (5.0y) ago | $884 | $1.8 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PPBT forecast.
Our base-case forecast reaches $3.20 around 2040.
Implied market cap at $3.20: $2.98M
The year-by-year forecast points to a mixed but progressively constructive longer-term path. In 2027 the average price is $2.26 with a 33.6% ROI and a bullish sentiment, followed by 2028 with an average of $2.32 and a 37% ROI, and 2029 with an average of $2.26 and a 33.6% ROI. For 2030 the average is $1.80 with a 6.3% ROI and neutral sentiment, and 2031 at $1.85 with a 9.3% ROI.
The 2032 forecast shows an uptick to $2.06 (22.1% ROI) and 2033 to $2.44 (44.6% ROI), with 2034 and 2035 both at an average of $2.88 and ROI of 70.4% (bullish). The longer horizon improves further, with 2040 averaging $3.69 and a 118.4% ROI, and 2050 averaging $5.37 with a 217.8% ROI, both with bullish sentiment. These are estimates and not guarantees, and actual results may differ given market and clinical development dynamics.
Tap a question to reveal the answer.
Average price: $1.80; Minimum: $1.11; Maximum: $3.12; ROI: 6.3%; Sentiment: NEUTRAL.
Yes. 2027 forecast shows an average price of $2.26 with a maximum of $3.38 and a minimum of $1.63; ROI 33.6%; sentiment BULLISH.
Average price: $3.69; Minimum: $1.66; Maximum: $8.11; ROI: 118.4%; Sentiment: BULLISH.
Current Price: $1.69; Market Cap: $1.58M.
Yes. The 2050 forecast maximum price is $12.35 with an average of $5.37 and a ROI of 217.8%; sentiment: BULLISH.
Purple Biotech Ltd Community Discussion
0Share your Purple Biotech Ltd price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.